Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment

ConditionGastroesophageal Reflux Disease

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorQilu Hospital of Shandong University

About this trial

The study objective is to evaluate the relative merits, safety and effectiveness of Anti-reflux mucosal valvuloplasty (ARMV) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs).

Eligibility criteria

Qualifiers

18-60 years of age;

Hiatal hernia ≤ 2 cm;

Sliding hernia ≤ 2 cm;

Recurrence of GERD symptoms after cessation of PPIs;

Disqualifiers

BMI > 35 kg/m2;

ASA > II;

Barrett's esophagus;

Hiatal hernia > 2 cm;

Trial design

Treatments tested in this trial

anti-reflux mucosal valvuloplasty (ARMV)

Treatment groups

74 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Qilu Hospital of Shandong University

Lead sponsor

Shandong University

Collaborator

Source ClinicalTrials.gov